Adeno-associated virus (AAV) vectors: Rational design strategies for capsid engineering

被引:41
|
作者
Lee, Esther J. [1 ]
Guenther, Caitlin M. [1 ]
Suh, Junghae [1 ]
机构
[1] Rice Univ, Dept Bioengn, 6500 Main St MS-142, Houston, TX 77030 USA
基金
美国国家卫生研究院; 美国国家科学基金会;
关键词
Adeno-associated virus; AAV; Gene therapy; Gene delivery; Rational design; Synthetic virology; Viral vector;
D O I
10.1016/j.cobme.2018.09.004
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Adeno-associated virus (AAV) consists of a simple genome, infects mammalian cells, displays nonpathogenicity in humans, and spans an array of serotypes and variants bearing distinct tissue tropisms. These attributes lend AAV tremendous promise as a gene delivery vector, further substantiated by its extensive testing in human clinical trials. Rational design approaches to capsid engineering leverage current scientific knowledge of AAV to further modulate, enhance and optimize the performance of the vectors. Capsid modification strategies include amino acid point mutations, peptide domain insertions, and chemical biology approaches. Through such efforts, insights regarding AAV capsid sequence-structure-function relationships can be learned. Developments over the last 5 years in rational design-based capsid engineering approaches will be presented and discussed.
引用
收藏
页码:58 / 63
页数:6
相关论文
共 50 条
  • [1] Modifying Immune Responses to Adeno-Associated Virus (AAV) Vectors by Capsid Engineering
    Bentler, Martin
    Hardet, Romain
    Ertelt, Moritz
    Kaniowska, Dorota
    Rudolf, Daniela
    Vondran, Florian W. R.
    Schoeder, Clara T.
    Delphin, Marion
    Lucifora, Julie
    Ott, Michael
    Hacker, Ulrich T.
    Adriouch, Sahil
    Buening, Hildegard
    MOLECULAR THERAPY, 2023, 31 (04) : 8 - 8
  • [2] A rational capsid-engineering strategy reduces innate and adaptive immune responses to Adeno-Associated Virus (AAV) Vectors
    Bentler, M.
    Hardet, R.
    Ertelt, M.
    Rudolf, D.
    Kaniowska, D.
    Schneider, A.
    Vondran, F. W. R.
    Schoeder, C. T.
    Delphin, M.
    Lucifora, J.
    Ott, M.
    Hacker, U. T.
    Adriouch, S.
    Buening, H.
    HUMAN GENE THERAPY, 2024, 35 (3-4) : A58 - A59
  • [3] Modifying immune responses to adeno-associated virus vectors by capsid engineering
    Bentler, Martin
    Hardet, Romain
    Ertelt, Moritz
    Rudolf, Daniela
    Kaniowska, Dorota
    Schneider, Andreas
    Vondran, Florian W. R.
    Schoeder, Clara T.
    Delphin, Marion
    Lucifora, Julie
    Ott, Michael
    Hacker, Ulrich T.
    Adriouch, Sahil
    Buening, Hildegard
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2023, 30 : 576 - 592
  • [4] Adeno-associated virus (AAV) vectors in the CNS
    McCown, TJ
    CURRENT GENE THERAPY, 2005, 5 (03) : 333 - 338
  • [5] Adeno-Associated Virus (AAV) Vectors in the CNS
    McCown, Thomas J.
    CURRENT GENE THERAPY, 2011, 11 (03) : 181 - 188
  • [6] The Utilization of Capsid-Optimized Adeno-Associated Virus (AAV) Vectors for Cancer Immunotherapy
    Pandya, Munjal
    Britt, Kellee
    Ling, Chen
    Hoffman, Brad
    Aslanidi, George
    MOLECULAR THERAPY, 2015, 23 : S87 - S87
  • [7] Integration of adeno-associated virus (AAV) and recombinant AAV vectors
    McCarty, DM
    Young, SM
    Samulski, RJ
    ANNUAL REVIEW OF GENETICS, 2004, 38 : 819 - 845
  • [8] Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications
    Schoen, Christian
    Biel, Martin
    Michalakis, Stylianos
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2015, 95 : 343 - 352
  • [9] Adeno-associated virus (AAV) vectors in gene therapy
    Serra, C
    Zentilin, L
    Tafuro, S
    Falaschi, A
    Giacca, M
    MINERVA BIOTECNOLOGICA, 1997, 9 (03) : 155 - 165
  • [10] Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy
    Rodriguez-Marquez, Esther
    Meumann, Nadja
    Buening, Hildegard
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (06) : 749 - 766